^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) +
    ispinesib (SB-715992) (KIF11 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancers (Basel)
    Title:

    Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia

    Published date:
    12/08/2021
    Excerpt:
    ...combination treatment with ispinesib and cabozantinib or ponatinib shows high synergy in FLT3-ITD+ AML cell lines and patient samples. Together, we suggest WS6, ispinesib, ponatinib and cabozantinib as novel options for targeting FLT3-ITD+ AML.
    DOI:
    https:// doi.org/10.3390/cancers13246181